The DOI matches its Crossref record.
Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein
Abstract
LDL (low-density lipoprotein) is the major carrier of cholesterol in human plasma, and as such is intimately involved in the process of atherosclerosis. The lipoprotein class comprises a number of distinct subfractions, and is commonly divided into large, intermediate and small sized particles. Small, dense LDLs are held to be particularly atherogenic, since these particles are retained preferentially by the artery wall, are readily oxidized and carry an enzyme believed to have an important role in atherosclerosis, i.e. lipoprotein-associated phospholipase A2. Generation of small, dense LDL occurs by intravascular lipoprotein remodelling as a result of disturbances such as Type II diabetes, metabolic syndrome, renal disease and pre-eclampsia. The key predisposing factor is the development of hypertriglyceridaemia, in particular elevation in the plasma concentration of large, triacylglycerol-rich VLDL (very-low-density lipoprotein). This leads to the formation of slowly metabolized LDL particles (5-day residence time), which are subject to exchange processes that remove cholesteryl ester from the particle core and replace it with triacylglycerol. LDL, so altered, is a potential substrate for hepatic lipase; if the activity of the enzyme is high enough, lipolysis will generate smaller, denser particles. Correction of the dyslipidaemia associated with small, dense LDL is possible using fibrates and statins, and this may contribute to the clinical benefits seen with these drugs. Fibrates act to lower plasma triacylglycerol (VLDL) levels, and so correct the underlying metabolic disturbance. Statins remove VLDL particles via receptor-mediated pathways and reduce the residence time (and hence limit the potential for remodelling) of LDL in the circulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Small dense LDL are relatively slowly metabolized with a five day residence time, which enhances its atherogenicity [54].”
From Dyslipidemia in obesity: Mechanisms and potential targets (2013) · cites this paper as [54]
Citations
Cites
Still being checked.
Cited by
Association between insulin resistance and the development of cardiovascular disease
Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., & Zuñiga, F. A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0762-4 · Cited by 2,280
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
“Small dense LDL are relatively slowly metabolized with a five day residence time, which enhances its atherogenicity [54].”
BackgroundOxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus
Tangvarasittichai, S. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.456 · Cited by 1,213
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716
Hepatic insulin resistance, metabolic syndrome and cardiovascular disease
Meshkani, R., & Adeli, K. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.05.018 · Cited by 458
Pessayre, D., & Fromenty, B. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.03.004 · Cited by 441
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
“The formation of small dense LDL is closely associated with insulin resistance and hypertriglyceridemia [233,234], and the VLDL1-triglyceride level is the major predictor of LDL size in individuals with or without type 2 diabetes [16,48,170,235,236].”
BackgroundDekker, M. J., Su, Q., Baker, C., Rutledge, A. C., & Adeli, K. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00283.2010 · Cited by 420
Duran, E. K., Aday, A. W., Cook, N. R., Buring, J. E., Ridker, P. M., & Pradhan, A. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.059 · Cited by 334
Lara-Castro, C., Fu, Y., Chung, B. H., & Garvey, W. T. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32814a645f · Cited by 315
Kathiresan, S., Otvos, J. D., Sullivan, L. M., Keyes, M. J., Schaefer, E. J., Wilson, P. W. F., D’Agostino, R. B., Vasan, R. S., & Robins, S. J. (2006) · Circulation · doi:10.1161/circulationaha.105.567107 · Cited by 318
Normal Pregnancy- A State of Insulin Resistance
Sonagra, A. D. (2014) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2014/10068.5081 · Cited by 268
Siddiqui, M. S., Fuchs, M., Idowu, M. O., Luketic, V. A., Boyett, S., Sargeant, C., Stravitz, R. T., Puri, P., Matherly, S., Sterling, R. K., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.10.008 · Cited by 231
Stanhope, K. L., & Havel, P. J. (2008) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.25825d · Cited by 237
Okazaki, M., Usui, S., Ishigami, M., Sakai, N., Nakamura, T., Matsuzawa, Y., & Yamashita, S. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000155017.60171.88 · Cited by 228
Stanhope, K. L., Griffen, S. C., Bair, B. R., Swarbrick, M. M., Keim, N. L., & Havel, P. J. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.5.1194 · Cited by 228
Pathophysiology of dyslipidaemia in the metabolic syndrome
Kolovou, G. D., Anagnostopoulou, K. K., & Cokkinos, D. V. (2005) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.025601 · Cited by 212
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
“In HTG, there is increased secretion of TG-enriched, larger VLDL particles, which are precursors of sdLDL, and increased delipidation of larger buoyant LDL to form sdLDL; furthermore, the liver directly secretes more LDL particles of smaller size in HTG (25,36,37).”
BackgroundRecent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 164
Mitochondrial injury in steatohepatitis
Pessayre, D., Fromenty, B., & Mansouri, A. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200411000-00003 · Cited by 161
Hypertriglyceridemia in the genomic era: a new paradigm
Lewis, G. F., Xiao, C., & Hegele, R. A. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1062 · Cited by 152
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
Siddiqui, M. S., Natta, M. L. V., Connelly, M. A., Vuppalanchi, R., Neuschwander‐Tetri, B. A., Tonascia, J., Guy, C. D., Loomba, R. S., Dasarathy, S., Wattacheril, J. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.006 · Cited by 147
n-3 Fatty Acids in the Treatment of Diabetic Patients
Caterina, R. D., Madonna, R., Bertolotto, A., & Schmidt, E. B. (2007) · Diabetes Care · doi:10.2337/dc06-1332 · Cited by 154
Améen, C., Edvardsson, U., Ljungberg, A., Asp, L., Åkerblad, P., Tuneld, A., Olofsson, S., Lindén, D., & Oscarsson, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m412107200 · Cited by 146
Wallenfeldt, K., Bokemark, L., Wikstrand, J., Hulthe, J., & Fagerberg, B. (2004) · Stroke · doi:10.1161/01.str.0000140629.65145.3c · Cited by 125
Rabbani, N., Chittari, M. V., Bodmer, C. W., Zehnder, D., Ceriello, A., & Thornalley, P. J. (2010) · Diabetes · doi:10.2337/db09-1455 · Cited by 125
Stanhope, K. L., & Havel, P. J. (2009) · Journal of Nutrition · doi:10.3945/jn.109.106641 · Cited by 144
The abnormal lipid profile in obesity and coronary heart disease (CHD) in Pakistani subjects
Shabana, S., Shahid, S. U., & Sarwar, S. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01248-0 · Cited by 130
Adipocytokines and VLDL Metabolism
Ng, T. W., Watts, G. F., Farvid, M. S., Chan, D. C., & Barrett, P. H. R. (2005) · Diabetes · doi:10.2337/diabetes.54.3.795 · Cited by 110
Edvardsson, U., Ljungberg, A., Lindén, D., William‐Olsson, L., Peilot, H., Ahnmark, A., & Oscarsson, J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500203-jlr200 · Cited by 118
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles
Gazi, I. F., Tsimihodimos, V., Tselepis, A. D., Elisaf, M., & Mikhailidis, D. P. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.1.53 · Cited by 105
Wood, R. J., Volek, J. S., Liu, Y., Shachter, N. S., Contois, J. H., & Fernández, M. L. (2006) · Journal of Nutrition · doi:10.1093/jn/136.2.384 · Cited by 107
Bays, H. E., Braeckman, R. A., Ballantyne, C. M., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.07.001 · Cited by 94
Luna-Castillo, K. P., Olivares-Ochoa, X. C., Hernández-Ruíz, R. G., Llamas-Covarrubias, I. M., Rodríguez-Reyes, S. C., Betancourt‐Núñez, A., Vizmanos-Lamotte, B., Martínez‐López, E., Muñóz-Valle, J. F., Márquez‐Sandoval, F., et al. (2022) · Nutrients · doi:10.3390/nu14051104 · Cited by 104
Siddiqui, M. S., Sterling, R. K., Luketic, V. A., Puri, P., Stravitz, R. T., Bouneva, I., Boyett, S. L., Fuchs, M. A., Sargeant, C., Warnick, G. R., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.036 · Cited by 98
Ito, F., & Ito, T. (2020) · Antioxidants · doi:10.3390/antiox9050362 · Cited by 87
Treviño, S., Waalkes, M. P., Hernández, J. A. F., León‐Chávez, B. A., Aguilar‐Alonso, P., & Brambila, E. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.07.010 · Cited by 82
Maki, K. C., Bays, H. E., Dicklin, M. R., Johnson, S. L., & Shabbout, M. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.09.001 · Cited by 81
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
Choi, Y., Roberts, B. K., Wang, X., Geaney, J. C., Naim, S., Wojnoonski, K., Karpf, D. B., & Krauss, R. M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.029 · Cited by 80
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010024 · Cited by 88
Jenseits von Gut und Böse: Bestimmung von Lipoprotein-Subklassen
Plonné, D. (2021) · Trillium Diagnostik · doi:10.47184/td.2021.01.01 · Cited by 76
Lipid Abnormalities in Type 2 Diabetes Mellitus Patients with Overt Nephropathy
Palazhy, S., & Viswanathan, V. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.2.128 · Cited by 76
Adiposopathy: why do adiposity and obesity cause metabolic disease?
Bays, H. E., & Ballantyne, C. M. (2006) · Future Lipidology · doi:10.2217/17460875.1.4.389 · Cited by 86
Davidson, M. H., Maki, K. C., Bays, H., Carter, R., & Ballantyne, C. M. (2009) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2009.08.001 · Cited by 71
Gender differences in the lipid profile of dyslipidemic subjects
Kolovou, G. D., Anagnostopoulou, K. K., Damaskos, D. S., Bilianou, H. I., Mihas, C. C., Milionis, H. J., Kostakou, P. M., & Cokkinos, D. V. (2008) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2008.06.011 · Cited by 70
Chan, D. C., & Watts, G. F. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.502529 · Cited by 69
“Dysregulation of VLDL metabolism in MetS therefore has a major qualitative and quantitative impact on the metabolism of LDL and HDL [26,49-51].”
BackgroundInfluentialSokooti, S., Flores-Guerrero, J. L., Heerspink, H. J. L., Connelly, M. A., Bakker, S. J. L., & Dullaart, R. P. F. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01348-w · Cited by 71
Yıldız, G., Duman, A., Aydın, H., Yılmaz, A., Hür, E., Mağden, K., Çetin, G., & Candan, F. (2013) · Hemodialysis International · doi:10.1111/hdi.12041 · Cited by 73
Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes
Younis, N. N., Soran, H., Pemberton, P. W., Charlton-Menys, V., Elseweidy, M. M., & Durrington, P. N. (2012) · Clinical Science · doi:10.1042/cs20120304 · Cited by 66
Pathophysiology and Medical Treatment of Carotid Artery Stenosis
Prasad, K. (2015) · International Journal of Angiology · doi:10.1055/s-0035-1554911 · Cited by 82
Xiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 60
Thongtang, N., Diffenderfer, M. R., Ooi, E. M. M., Barrett, P. H. R., Turner, S., Le, N., Brown, W. V., & Schaefer, E. J. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m073882 · Cited by 66
Thota, R. N., Ferguson, J. J. A., Abbott, K. A., Dias, C. B., & Garg, M. L. (2018) · Food & Function · doi:10.1039/c8fo00348c · Cited by 65
Peroxisome proliferator-activated receptors: Bridging metabolic syndrome with molecular nutrition
Guri, A. J., Hontecillas, R., & Bassaganya-Riera, J. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2006.08.006 · Cited by 65
Cao, S., Xu, P., Yan, J., Liu, H., Liu, L., Cheng, L., Qiu, F., & Kang, N. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27102 · Cited by 57
Davidson, M. H., Rooney, M. W., Drucker, J. L., Griffin, H. E., Oosman, S., & Beckert, M. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.12.007 · Cited by 55
Dunbar, R. L., Nicholls, S. J., Maki, K. C., Roth, E. M., Orloff, D. G., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0100-8 · Cited by 52
Niikura, T., Imajo, K., Ozaki, A., Kobayashi, T., Iwaki, M., Honda, Y., Kessoku, T., Ogawa, Y., Yoneda, M., Kirikoshi, H., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10030129 · Cited by 52
Kostapanos, M. S., Milionis, H. J., Filippatos, T. D., Nakou, E. S., Bairaktari, E. T., Tselepis, A. D., & Elisaf, M. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.019 · Cited by 54
Basal and Insulin Mediated VLDL-Triglyceride Kinetics in Type 2 Diabetic Men
Sørensen, L. P., Andersen, I. R., Søndergaard, E., Gormsen, L. C., Schmitz, O., Christiansen, J. S., & Nielsen, S. (2011) · Diabetes · doi:10.2337/db10-0564 · Cited by 51
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
Davidson, M. H., Bays, H. E., Stein, E., Maki, K. C., Shalwitz, R. A., & Doyle, R. (2006) · Clinical Cardiology · doi:10.1002/clc.4960290609 · Cited by 51
Chhatrala, R., Siddiqui, M. B., Stravitz, R. T., Driscoll, C. J., Sanyal, A. J., Sargeant, C., Luketic, V. A., Sharma, A., Sterling, R. K., Matherly, S. C., et al. (2015) · Liver Transplantation · doi:10.1002/lt.24100 · Cited by 50
Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome
Rizos, E. C., Tambaki, A. P., Gazi, I. F., Tselepis, A. D., & Elisaf, M. (2004) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2004.10.021 · Cited by 50
Akhter, F., Khan, M. S., Alatar, A. A., Faisal, M., & Ahmad, S. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.02.013 · Cited by 50
Phelan, N., O’Connor, A. S., Tun, T. K., Correia, N., Boran, G. P., Roche, H. M., & Gibney, J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2444 · Cited by 51
Imajo, K., Hyogo, H., Yoneda, M., Honda, Y., Kessoku, T., Tomeno, W., Ogawa, Y., Taguri, M., Mawatari, H., Nozaki, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115403 · Cited by 48
Park, H., Ishigami, A., Shima, T., Mizuno, M., Maruyama, N., Yamaguchi, K., Mitsuyoshi, H., Minami, M., Yasui, K., Itoh, Y., et al. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0154-3 · Cited by 51
Zhou, P., Liu, J., Wang, L., Feng, W., Cao, Z., Wang, P., Liu, G., Sun, C., Shen, Y., Wang, L., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.53132 · Cited by 46
Siddiqui, M. B., Arshad, T., Patel, S. S., Lee, E., Albhaisi, S. A. M., Sanyal, A. J., Stravitz, R. T., Driscoll, C. J., Sterling, R. K., Reichman, T., et al. (2019) · Hepatology · doi:10.1002/hep.30518 · Cited by 43
The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.001 · Cited by 49
Theuwissen, E., Plat, J., Kallen, C., van Greevenbroek, M. M. J., & Mensink, R. P. (2009) · Lipids · doi:10.1007/s11745-009-3367-6 · Cited by 39
De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients
Idowu, M. O., Chhatrala, R., Siddiqui, M. B., Driscoll, C. J., Stravitz, R. T., Sanyal, A. J., Bhati, C. S., Sargeant, C., Luketic, V. A., Sterling, R. K., et al. (2015) · Liver Transplantation · doi:10.1002/lt.24223 · Cited by 43
Li, J., Zhao, Z., Jiang, H., Jiang, M., Yu, G., & Li, X. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-01903-z · Cited by 45
Usefulness of the LDL-C/apoB ratio in the overall evaluation of atherogenicity of lipid profile
Kaneva, A. M., Потолицына, Н. Н., & Bojko, E. R. (2016) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2016.1195411 · Cited by 38
Lucero, D., Miksztowicz, V., Gualano, G., Longo, C., Landeira, G., Álvarez, E., Zago, V., Brites, F. D., Berg, G. A., Fassio, E., et al. (2017) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.08.006 · Cited by 40
Ferguson, J. J. A., Wolska, A. T., Remaley, A. T., Stojanovski, E., MacDonald‐Wicks, L. K., & Garg, M. L. (2019) · Food & Function · doi:10.1039/c8fo02512f · Cited by 40
Changes on serum and hepatic lipidome after a chronic cadmium exposure in Wistar rats
Sarmiento-Ortega, V. E., Treviño, S., Flores-Hernández, J. Á., Aguilar‐Alonso, P., Moroni-González, D., Aburto-Luna, V., Díaz, A., & Brambila, E. (2017) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2017.10.003 · Cited by 38
Hayashi, T., Hirano, T., Yamamoto, T., Ito, Y., & Adachi, M. (2006) · Metabolism · doi:10.1016/j.metabol.2006.02.014 · Cited by 38
Santos, R. D., Raal, F. J., Donovan, J. M., & Cromwell, W. C. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.12.008 · Cited by 40
Heidari, A. (2020) · Advanced Science Engineering and Medicine · doi:10.1166/asem.2020.2635 · Cited by 38
Rocha, M., Bañuls, C., Bellod, L., Rovira‐Llopis, S., Morillas, C., Solá, E., Víctor, V. M., & Hernández‐Mijares, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078670 · Cited by 37
Thambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 51
Pancreas–Liver–Adipose Axis: Target of Environmental Cadmium Exposure Linked to Metabolic Diseases
Moroni-González, D., Sarmiento-Ortega, V. E., Díaz, A., Brambila, E., & Treviño, S. (2023) · Toxics · doi:10.3390/toxics11030223 · Cited by 35
Increased Lipid Peroxidation in LDL from Type‐2 Diabetic Patients
Colas, R. A., Pruneta‐Deloche, V., Guichardant, M., Luquain‐Costaz, C., Cugnet‐Anceau, C., Moret, M., Vidal, H., Moulin, P., Lagarde, M., & Calzada, C. (2010) · Lipids · doi:10.1007/s11745-010-3453-9 · Cited by 34
Novel developments in omega-3 fatty acid-based strategies
Davidson, M. H., Kling, D. F., & Maki, K. C. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834bd642 · Cited by 35
Peroxisome proliferator-activated receptor α polymorphisms and postprandial lipemia in healthy men
Tanaka, T., Ordovás, J. M., Delgado‐Lista, J., Pérez‐Jiménez, F., Marín, C., Pérez‐Martínez, P., Gómez, P., & López‐Miranda, J. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700066-jlr200 · Cited by 36
Fuentes, M. C., Lajo, T., Carrión, J. M., & Cuñé, J. (2016) · Mediterranean Journal of Nutrition and Metabolism · doi:10.3233/mnm-160065 · Cited by 31
Tolonen, N., Forsblom, C. M., Mäkinen, V., Harjutsalo, V., Gordin, D., Feodoroff, M., Sandholm, N., Thorn, L. M., Wadén, J., Taskinen, M., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2873 · Cited by 34
Rufail, M. L., Schenkein, H. A., Barbour, S. E., Tew, J. G., & van Antwerpen, R. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500389-jlr200 · Cited by 31
WHO (WORLD HEALTH ORGANIZATION)
(2007) · Routledge eBooks · doi:10.4324/9780203098837-59 · Cited by 30
Computational Lipidology: Predicting Lipoprotein Density Profiles in Human Blood Plasma
Hübner, K., Schwager, T., Winkler, K., Jg, R., & Holzhütter, H. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000079 · Cited by 30
Hirano, T., & Ito, Y. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63865 · Cited by 29
Lucero, D., Zago, V., López, G. H., Cacciagiú, L. D., Lopez, G. I., Wikinski, R., Nakajima, K., & Schreier, L. E. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2011.12.013 · Cited by 32
Hirano, T., Kodera, R., Hirashima, T., Suzuki, N., Aoki, E., Hosoya, M., Oshima, T., Hayashi, T., Koba, S., Ohta, M., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.62789 · Cited by 31
Torcetrapib/atorvastatin combination therapy
Bays, H. E., McKenney, J. M., & Davidson, M. H. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.5.789 · Cited by 28
Fazio, S. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.02.004 · Cited by 33
Relationship between CETP gene polymorphisms with coronary artery disease in Polish population
Iwanicka, J., Iwanicki, T., Niemiec, P., Balcerzyk, A., Krauze, J., Górczyńska-Kosiorz, S. B., Ochalska-Tyka, A., Grzeszczak, W., & Żak, I. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4342-1 · Cited by 27
Wu, J., Shi, Y., Niu, D.-M., Li, H., Zhang, C.-N., & Wang, J. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.02.022 · Cited by 27
Metadata
- Authors
- Packard, C. J.
- Affiliations
- Glasgow Royal Infirmary (GB)
- Corresponding author
- Packard, C.J.
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2003-10-01
- Volume
- 31
- Issue
- 5
- Pages
- 1066-1069
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W2121209370
- Cited by
- 225
- References
- 0
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 3 · 2021: 13 · 2020: 12 · 2019: 6 · 2018: 7 · 2017: 12 · 2016: 9 · 2015: 15 · 2014: 13 · 2013: 10 · 2012: 11
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemical Society Transactions (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- small dense LDL, triglyceride-rich lipoproteins, VLDL, hypertriglyceridemia, hepatic lipase, lipolysis, atherosclerosis, lipoprotein-associated phospholipase A2, fibrates, statins, dyslipidemia, cholesterol esters
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Lipoproteins, Lipoproteins, LDL, Models, Biological, Phospholipases A, Triglycerides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.